# A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers

> **NCT06518122** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 66 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HCP1306
- **DRUG:** RLD2302
- **DRUG:** RLD2102

## Key facts

- **NCT ID:** NCT06518122
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-09-01
- **Primary completion:** 2025-01-03
- **Final completion:** 2025-01-03
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06518122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06518122, "A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT06518122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*